Tejara Capital Ltd Buys 2,500,000 Shares of Cardiol Therapeutics Inc. $CRDL

Tejara Capital Ltd boosted its stake in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 95.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,130,122 shares of the company’s stock after purchasing an additional 2,500,000 shares during the quarter. Cardiol Therapeutics comprises approximately 1.2% of Tejara Capital Ltd’s portfolio, making the stock its 17th biggest holding. Tejara Capital Ltd owned approximately 4.59% of Cardiol Therapeutics worth $4,893,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of Cardiol Therapeutics by 1,983.0% in the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock worth $590,000 after buying an additional 524,598 shares during the last quarter. Citadel Advisors LLC grew its position in Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock worth $496,000 after acquiring an additional 425,862 shares in the last quarter. Two Sigma Investments LP bought a new position in Cardiol Therapeutics in the third quarter valued at $249,000. Virtu Financial LLC purchased a new stake in Cardiol Therapeutics during the third quarter valued at about $154,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after purchasing an additional 73,375 shares in the last quarter. 12.49% of the stock is currently owned by institutional investors.

Cardiol Therapeutics Stock Up 0.7%

Cardiol Therapeutics stock opened at $1.37 on Friday. The firm has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.10. Cardiol Therapeutics Inc. has a twelve month low of $0.88 and a twelve month high of $1.71. The company has a market capitalization of $153.19 million, a PE ratio of -4.89 and a beta of 0.77.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). As a group, equities analysts expect that Cardiol Therapeutics Inc. will post -0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CRDL. upgraded Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research report on Tuesday, February 10th. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price target on shares of Cardiol Therapeutics in a research note on Monday, April 6th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.50.

Cardiol Therapeutics Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.